DestiNA Genomics

About:

We aim to transform how miRNAs are detected, providing simpler tools for health care and drug development professionals.

Website: https://destinagenomics.com/

Twitter/X: DestiNAGenomica

Top Investors: Old College Capital, Scottish Investment Bank, Vitro Group

Description:

DestiNA Genomics Ltd (DGL) is a University of Edinburgh spin-out company, formed to commercialise a revolutionary chemical based system for detecting nucleic acids and single nucleotide polymorphisms (SNP’s). DGL has entered into an exclusive Licence Agreement with the University of Edinburgh, covering the development and commercialisation arising from the patent “Nucleobase Characterisation”. The technology is unique and distinguishable from ALL existing enzymatic methods of nucleic acid analysis. DGL intends to develop and launch a completely ‘PCR free’ system for nucleic acid analysis, using the unique properties of the nucleobase chemistry. In particular, DGL has identified that its reagents are particularly suited for direct detection of micro-RNA’s.DestiNA is working with trade partners to integrate their technology within colorimetric, fluorescent and electrochemical-based detection platforms. DestiNA Genomics Ltd has incorporated a Spanish company called DestiNA Genomica SL with the goal of exploit our technology in Spain with different partners such as Master Diagnostica. DestiNA Genomica SL. was awarded a grant from the Technological Fund of Invest in Spain (1-2011/55 €239,000). The Technological Fund of Invest in Spain is a special area of ERDF funds from the European Union created to promote business R&D&I in Spain for the 2007-2013 period.